TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01871883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral mucosa specimen
Description: The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral mucosa specimen
Description: The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
Study: NCT01587066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex sodium
Description: Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
Study: NCT02239172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA83-FhCMB
Study: NCT01423006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-Frequency Ablation (RFA) ENCAGE™
Description: RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
Study: NCT04463602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desidustat
Description: 100 mg once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care as per local authority
Study: NCT03518476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Participants in control arm will receive a non-tobacco related training or educational session
Study: NCT02239172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA83-FhCMB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA83-FhCMB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PA83-FhCMB
Study: NCT02208960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal Kit
Description: Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal Kit
Description: Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neonatal Stimulation
Description: A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neonatal Stimulation
Description: A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch
Study: NCT05046028

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet
Description: ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS without a sensor component and taste + standard diet
Description: Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard diet
Description: Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
Study: NCT02268162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding equipments
Description: The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding equipments
Description: The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
Study: NCT00793793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
Study: NCT04463602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as per local authority
Study: NCT00793793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI201335
Description: patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02200484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined parent training and obesity prevention program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness program (active contact control)
Study: NCT04426305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community health worker support
Description: usual care by professional primary care providers + emotional support by trained community health worker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care as usual
Description: care as usual is provided by professional primary care provider
Study: NCT03892837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment for benign airway stenosis
Description: Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
Study: NCT02746484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ability platform program
Description: The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care program
Description: Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
Study: NCT03892837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional treatment for benign airway stenosis
Description: Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
Study: NCT01910792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sperti Lamp
Description: UV light exposure 3 times per week for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sperti Lamp
Description: UV light exposure 3 times per week for 12 weeks
Study: NCT01552057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Description: Duloxetine 60 mg taken orally once every day for 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally once every day for 15 weeks
Study: NCT00103012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gingko Biloba
Description: Ginkgo Biloba 120 mg twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Description: Echinacea purpurea 500 mg three times daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Description: Panax ginseng 500 mg twice daily
Study: NCT00970606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (crestor)
Description: 20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to active therapy. 1 tablet per day
Study: NCT02472457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crohn Disease Exclusion Diet
Description: The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free Diet
Description: This diet contains no restrictions.
Study: NCT02005822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
Study: NCT02487186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxicicline
Description: Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth debridment
Description: The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth debridment
Description: The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed.
Study: NCT01061931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front® catheter vs. HD Mesh Ablator® catheter
Description: Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front® catheter vs. HD Mesh Ablator® catheter
Description: Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
Study: NCT02661594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 5 mg
Description: Therapeutic dose of amisulpride
Study: NCT02017717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study: NCT02661594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 5 mg
Description: Therapeutic dose of amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 5 mg
Description: Therapeutic dose of amisulpride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APD421 5 mg
Description: Therapeutic dose of amisulpride
Study: NCT02529592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02648334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT drug coated balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix drug coated balloon
Study: NCT02661594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 40 mg
Description: Supra-therapeutic dose of amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 40 mg
Description: Supra-therapeutic dose of amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421 40 mg
Description: Supra-therapeutic dose of amisulpride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APD421 40 mg
Description: Supra-therapeutic dose of amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Positive control for assay sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Positive control for assay sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Positive control for assay sensitivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Positive control for assay sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to establish baseline for calculating change in QTcF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to establish baseline for calculating change in QTcF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to establish baseline for calculating change in QTcF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to establish baseline for calculating change in QTcF
Study: NCT04120922

Intervention type: OTHER
Group type: OTHER
Intervention: calcium carbonate
Description: See arm description
Study: NCT04445389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-19
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-19
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GX-19
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT00282464

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geodon (Ziprasidone)
Description: Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
Study: NCT00839033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical insufflation - exsufflation
Description: Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory physiotherapy
Description: Traditional chest physiotherapy without mechanical insufflation-exsufflation
Study: NCT03920540

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GC1111
Description: GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
Study: NCT01512667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0822
Description: A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0822
Description: A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
Study: NCT04425447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent local anesthesia
Description: Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic interfascial plane block
Description: Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A